Erol, Veysel
Loading...
Profile URL
Name Variants
Erol, V. Erol, Veysel. V. Erol
Job Title
Email Address
verol@pau.edu.tr
Main Affiliation
14.02. Internal Medicine
Status
Former Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
No research topics data found.
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
4
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
17PARTNERSHIPS FOR THE GOALS
0
Research Products
This researcher does not have a Scopus ID.
This researcher does not have a WoS ID.
No records found in other affiliations.
Scholarly Output
9
Articles
8
Views / Downloads
702/236
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
27
Scopus Citation Count
31
Patents
0
Projects
0
WoS Citations per Publication
3.00
Scopus Citations per Publication
3.44
Open Access Source
8
Supervised Theses
0
| Journal | Count |
|---|---|
| Case Reports in Medicine | 1 |
| Cureus Journal of Medical Science | 1 |
| Journal Of Oncology Pharmacy Practice | 1 |
| Pamukkale Tıp Dergisi | 1 |
| Saudi Journal of Kidney Diseases and Transplantation | 1 |
Current Page: 1 / 2
Scopus Quartile Distribution
Competency Cloud
9 results
Scholarly Output Search Results
Now showing 1 - 9 of 9
Article Citation - WoS: 8Citation - Scopus: 9Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies(Turkish Society of Hematology, 2022-02-24) Bozdag, Sinem Civriz; Seval, Guldane Cengiz; Hindilerden, Ipek Yonal; Hindilerden, Fehmi; Andic, Neslihan; Baydar, Mustafa; Kaynar, Lale AydinObjective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARS-CoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixty-nine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality. © 2022 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.Article Citation - WoS: 5Citation - Scopus: 5Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors(Sage Publications Ltd, 2022-07-12) Aslan, Nevin Alayvaz; Hincal, Hande Ogul; Elver, Ozde; Erol, Veysel; Guler, NilBackground: The discovery of tyrosine kinase inhibitors provided a breakthrough in the treatment of chronic myeloid leukemia. Nowadays, the management of tyrosine kinase inhibitor-related side effects is one of the important problems in chronic myeloid leukemia treatment. Grades 3-4 pulmonary toxicity; especially pleural effusion is mostly seen with dasatinib treatment but rarely seen with nilotinib and bosutinib. Development of cross-intolerance due to pleural effusion is not an expected situation. Pleural effusion related to tyrosine kinase inhibitors is mostly exudative in nature with abundant lymphocytes. Case report: Massive pleural effusion developed in a 59-year-old male patient with chronic myeloid leukemia, who was being treated with bosutinib. In the past, the patient had experienced massive pleural effusion also with dasatinib and nilotinib. The evaluation for differential diagnosis of pleural effusion did not reveal any additional malignancy. Management and outcome: After discontinuation of bosutinib and initiation of prednisolone, pleural effusion was totally resolved. Prednisolone was gradually discontinued and third-generation tyrosine kinase inhibitor ponatinib was started. After 12 months of follow-up, massive pleural effusion occurred again, leading to discontinuation of ponatinib. Discussion: Cross-intolerance is an important problem in the tyrosine kinase inhibitor era. The significance of this case is the development of cross-intolerance to all second-generation tyrosine kinase inhibitors and furthermore to a third-generation tyrosine kinase inhibitor. Management strategies for pleural effusion and close follow-up are important.Article The Relationship of Renalase With Diurnal Blood Pressure Rhythm, Left Ventricular Mass Index and Carotid Intima-Media Thickness in Autosomal Dominant Polycystic Kidney Disease(Wolters Kluwer Medknow Publications, 2025-01) Erol, Veysel; Ceri, Mevlut; Mert, Mehmet; Kilic, Oguz; Kilic, Ismail Dogu; Hasbey, Ibrahim; Sabir, NuranThis study investigated the relationship between renalase and diurnal blood pressure (BP) rhythm, left ventricular mass index (LVMI) and carotid intima-media thickness (IMT) in autosomal dominant polycstic kidney disease (ADPKD) patients. The study included 59 ADPKD patients and 36 healthy volunteers. Renalase, noradrenalin, adrenaline, creatinine (Cr) and spot urine microalbumin-Cr ratio were studied; 24-h ambulatory BP and carotid IMT were measured, and LVMI was calculated. The ADPKD group comprised 21 hypertensive and 38 normotensive patients, and the control group comprised 36 healthy participants. Renalase levels were significantly higher in hypertensive and normotensive ADPKD patients than in the control group (69.7 +/- 90.02 ng/mL and 91.93 +/- 106.55 ng/mL vs. 16.9 +/- 51.4 ng/mL; P = 0.042 and P = 0.001, respectively). The renalase levels were higher in the hypertensive ADPKD group than in the normotensive ADPKD group but they were not statistically significant (91.93 +/- 106.55 ng/mL vs. 69.7 +/- 90.02 ng/mL; P = 0.486). LVMI was significantly higher in the hypertensive ADPKD group compared with the normotensive ADPKD and control groups (92.2 +/- 20.9 vs. 76.2 +/- 16.89 and 68.6 +/- 12.75; P = 0.02 and P = 0.001, respectively). There was no statistically significant difference in carotid IMT between the groups (0.59 +/- 0.16, 0.65 +/- 0.17 and 0.58 +/- 0.1; P = 0.442, respectively). Renalase levels were significantly higher in the normotensive ADPKD and hypertensive ADPKD groups compared with the control group, but its relationship with circadian BP rhythm, LVMI and carotid IMT was not demonstrated.Article First case of flt3-tyrosine kinase domain mutant acute myeloid leukemia with unusual onset as isolated bilateral testicular myeloid sarcoma(Springernature, 2024-04-12) Erol, Veysel; Cagliyan, Gulsum Akgun; Ufuk, Furkan; Demir, DeryaTesticular myeloid sarcoma (TMS) is a challenging pathology often posing diagnostic difficulties due to the poorly differentiated nature of tumor cells at the initial presentation. The delay in diagnosis significantly impacts patient life expectancy, emphasizing the need for prompt identification and treatment initiation. In certain cases, the presence of the Fms-like tyrosine kinase ( FLT3 ) mutation adds complexity to the disease, requiring tailored therapeutic approaches. In this report, we present a unique case of bilateral TMS with FLT3 tyrosine kinase domain ( TKD ) mutation. The patient exhibited an aggressive clinical course, initially misdiagnosed with orchitis during the initial evaluation. Subsequent reevaluation of the testicular biopsy at a second center led to an accurate diagnosis, highlighting the importance of thorough examination in challenging cases. Given the emerging significance of FLT3 mutations in myeloid sarcomas, comprehensive testing for all FLT3 variants is crucial to determine the appropriate treatment modality. This case underscores the need for increased awareness among healthcare professionals regarding the diagnostic nuances and potential genetic variations associated with TMS. Furthermore, the inclusion of tyrosine kinase inhibitors, such as midostaurin or gilteritinib, especially in the presence of FLT3 mutations, may significantly impact treatment outcomes. This report contributes to the growing body of literature on TMS and highlights the importance of considering FLT3 mutations in the diagnostic and therapeutic decision -making process for improved patient care.Article Anti-CD38 monoclonal antibody daratumumab enhances the overall response rate in patients with multiple myeloma(Pamukkale University, 2024-04-01) Ö., Elver; N.A., Aslan; V., Erol; İ.C., Kendir; N., GülerPurpose: New medicines employed in recent years have resulted in significant increases in survival rates for Multiple Myeloma (MM). Daratumumab, a monoclonal antibody against CD38, is utilized in both first-line myeloma treatment and relapsed/refractory illness. Our study aims to assess the clinical features, response to treatment and factors influencing response to treatment in patients who received daratumumab monotherapy or combination therapy at our center. Materials and methods: In the Pamukkale University Faculty of Medicine Hematology clinic between June 2022 and June 2023, 21 patients who were treated with daratumumab after receiving a multiple myeloma diagnosis were included. Demographic features of the patients, disease stage, prior therapies, characteristics of daratumumab treatment, and response rates to treatments were retrospectively analyzed. Results: The patients median age was 65±9.7 years (42-80), with a female/male ratio of 11/10. Treatment with daratumumab: 61.9% was used after two lines of therapy, 23.8% was used in first-line therapy, and 14.28% was used in second-line therapy. The average number of cycles was 4.05±5.06. Of the patients treated with daratumumab, 4.76% were treated as a single agent; 61.9% were treated in combination with immunomodulatory medications, cyclophosphamide and/or melphalan; and 33.4% were treated in conjunction with chemotherapy. When the response to treatment was evaluated, 38.1% of the patients passed away, 38.1% had a very good partial response (VGPR) or better, and 23.8% had a partial response (PR). 42.9% of patients who received daratumumab along with chemotherapy died. With daratumumab-containing regimens, overall response rates increased significantly as the number of cycles increased (ORR) (p=0.026). Conclusion: When daratumumab-containing protocols are used in the treatment of multiple myeloma, it has been observed that overall response rates improve and treatment success increases in direct proportion to the number of cures.Specialist Thesis Otozomal dominant polikistik böbrek hastalığında renalazın diürnal kan basıncı ritmi, sol ventrikül kitle indeksi ve ateroskleroz ile ilişkisi(Pamukkale Üniversitesi Tıp Fakültesi, 2019) Erol, Veysel; Mevlüt Çeriİntroduction Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease characterized by progressive cyst formation in bilateral kidneys and is one of the common causes of end-stage renal disease (ESRD). The renalase is an enzyme that has recently been discovered, most of which is synthesized from renal tubules and metabolizes catecholamines, which is involved in the regulation of blood pressure. To date, there are studies showing the relationship of renalase between hypertension and cardiovascular mortality, although there is no data on this subject in ADPKD. In this study, we aimed to investigate the relationship of renalase enzyme with blood pressure diurnal rhythm, left ventricular mass index and atherosclerosis in ADPKD patients. Methods A total of 59 ADPKD patients (mean age 37.7, 72.9%) and 36 healthy volunteers, who were admitted to the Nephrology Clinic of Pamukkale University Medical Faculty Department of Internal Medicine between January 2017 and January 2018, were included in our prospective study. In all patients, renalase, noradrenalin, adrenaline, creatinine (Cr), Na, K, uric acid, TSH, fT4, LDL, HDL, triglyceride, total cholesterol, glucose, albumin, hemogram and spot urine microalbumin / Cr ratio were studied. 24-hour ambulatory blood pressure was measured by Mobil-O-Graph 24h PWA Monitor, I.E.M. GmbH, Stolberg, Germany in all participants. Carotid artery intima-media thickness measured by doppler USG and left ventricular mass (LVM) and left ventricular mass index (LVMI) were calculated by echocardiography. In statistical evaluation, the data were analyzed by SPSS Version 22.0, Inc. Chicago, IL, USA.Article Choroidal Recurrence of Testicular Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge in an Immune-Privileged Site(Wiley, 2025-01) Erol, Veysel; Parca, Osman; Aslan, Nevin Alayvaz; Turk, Nilay SenThe recent inclusion of immune-privileged site lymphoma in the World Health Organization classification signifies a distinctive entity encompassing the central nervous system and testicles. This classification is rooted in the unique challenges posed by the blood-brain barrier and blood-testis barrier, along with the distinct cancer microenvironment compared to standard lymphomas. These intricacies contribute to the complexity of treatment strategies, and as of now, a standardized protocol remains elusive. Our presented case underscores the critical need for a comprehensive treatment plan in immune-privileged site lymphomas, where surgery alone, in the form of indolent intervention, may fall short in addressing the underlying aggressive nature of the disease. Failure to administer systemic treatment, where indicated, heightens the risk of aggressive recurrence and substantially elevates mortality rates. Through a detailed examination of our case, we aim to contribute to the evolving body of knowledge surrounding these unique lymphomas, offering valuable insights that may guide future treatment strategies and improve patient outcomes.Article Akut Miyeloid Lösemili Hastalarda Kültür Pozitifliğinin Tedaviye Yanıt ve Sağkalıma Etkisi; Tek Merkez Verileri, Geriye Dönük Araştırma(2022-12-20) Aslan, Nevin Alayvaz; Senol, Hande; Erol, Veysel; Güler, Nil; Elver, Özde; Kendir, İsmail CanAmaç: Akut miyeloid lösemi (AML) indüksiyon ve kurtarma tedavileri ile uzamış ve derin nöt- ropeni gelişmekte, bu dönemde ortaya çıkan enfeksiyonlar mortalitenin önemli bir nedenini oluşturmaktadır. Çalışmamızda merkezimizde yatırılarak tedavi edilen yeni tanı veya nüks AML tanılı hastalarda takipleri boyunca alınan kan, idrar ve balgam kültürlerinde üreme saptanmasına etkili faktörleri ve kültür pozitifliğinin hastalık sonlanımına olan etkisini incelemeyi amaçladık. Hastalar ve Yöntem: Eylül 2019-Nisan 2022 tarihleri arasında Pamukkale Üniversitesi erişkin hematoloji bölümünde yatırılarak indüksiyon veya kurtarma tedavisi verilmiş olan AML tanılı 50 hastanın verileri geriye dönük olarak incelendi. Bulgular: Ortanca yaşı 67 olan 50 AML hastasının %46’sında en az bir vücut sıvısı kültüründe mikroorganizma saptandı. Hastaların hastalık durumlarının, yaş ve cinsiyetlerinin, hastaneye yatıştaki laboratuar sonuçlarının kültür pozitifliği görülme oranını etkilemediği ancak kemote- rapi içeren tedaviler alan hastalarda hipometile edici ajan ile tedavi edilen hastalara göre daha yüksek oranda kültür pozitifiliği saptandığı görüldü (%55.9’a karşı %25, p= 0.041). Kan kültürü pozitif saptanan hastaların tedavi sonunda %29.4’ü kaybedilirken, kan kültüründe mikroorganiz- ma saptanmayan hastalarda bu oran %6.1 olarak saptandı (p= 0.037). Sonuç: Çalışmada elde edilen veriler özellikle kültür pozitifliği saptanan olgularda sağkalımın kötü olduğunu bir kez daha göstermiştir. Ciddi enfeksiyon gelişme riskini arttıran durumları belirlemek ve bu durumlara yönelik koruyucu sağlık politikaları geliştirmek gerekmektedir. Bu çalışmada elde edilen veriler; AML tanılı hastalarda ateşli dönemde alınan kültür sonuçlarının takibi ve enfeksiyon kontrol önlemlerinin uygulanması gerektiğini göstermesi açısından önem- lidir.Article Citation - WoS: 14Citation - Scopus: 17Is CONUT score a prognostic index in patients with diffuse large cell lymphoma?(Tubitak Scientific & Technical Research Council Turkey, 2021-08-30) Akgun Cagiyan, Gulsum; Hacioglu, Sibel; Unver Koluman, Basak; Ilkkilic, Kadir; Nar, Rukiye; Baser, Mehmet Nuri; Bozdemir, AsliBackground/aim: The aim of the study was to evaluate the effect of Controlling Nutritional Status (CONUT) score on the prognosis in patients with diffuse large B-cell lymphoma (DLBCL). Materials and methods: The present study was a retrospective study. The CONUT score was calculated based on serum albumin, total cholesterol and lymphocyte levels. This study included a total of 266 patients, 131 (49.2%) were female and 135 (50.8%) were male. The median follow-up period was 51 months (range: 1-190). Results: The median age was 64 years. The cut off CONUT was 1.5. There was a significant difference between patients with high (>_ 2) or low (< 2) CONUT scores in terms of overall survival (OS) and progression-free survival (PFS). The 5-year OS and PFS in patients with high CONUT score was 52.1% and 49.7%. The 5-year OS and PFS in patients with low CONUT score was 79.8% and 75.6% (p < 0.001). In the multivariate analysis for OS, age >_ 65 years (HR = 1.80, p = 0.028), Eastern Cooperative Oncology Group (ECOG) > 1 (HR = 2.04, p = 0.006), stage IIIA-IVB disease (HR = 2.75, p = 0.001) and the CONUT score (HR = 1.15, p = 0.003) were found statistically significant. In the multivariate analysis for PFS, age >_ 65 years (HR = 2.02, p = 0.007), stage IIIA-IVB disease (HR = 2.42, p = 0.002) and the CONUT score (HR = 1.19, p = 0.001) were found to be significant parameters. Conclusion: High CONUT score reduces OS and PFS in DLBCL. CONUT score is an independent, strong prognostic index in patients with DLBCL.